Nothing specifically related to financing; however, they did appoint Han Wijers (Heineken, Nobel, Shell, Boston Consulting Group among others) to the Board effective April.
Commenting on the appointment, Sir Christopher Gent, Chairman of GSK, said:
“I am delighted to welcome Hans to the Board. His broad business experience, including as chief executive of AkzoNobel, together with his economic and political knowledge will enable him to make a significant contribution to the future success of GSK.”
The rumor was a $8 Billion M&A of another company...but it doesn't make as much sense as an Amarin BID. To match this, rumor has it Lovaza site back up Monday the 28th. What else's happens Monday? The Anchor patents are adding significant value, most M&A happen either before a big approval or after a year after launch...right? Year after launch, with Amarin, isn't going to work because it coincides with a 10 bigger approval of the Anchor indication. The time is now, IMO. No smoke behind this fire, just a wood pile of rumors;)